+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vitiligo - Pipeline Review, H1 2020

  • ID: 5024702
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 144 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 2A Pharma AB
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • JN Biosciences LLC
  • Radikal Therapeutics Inc
  • Temprian Therapeutics Inc
  • MORE
Vitiligo - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H1 2020, provides an overview of the Vitiligo (Dermatology) pipeline landscape.

Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 9 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 2A Pharma AB
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • JN Biosciences LLC
  • Radikal Therapeutics Inc
  • Temprian Therapeutics Inc
  • MORE
  • Introduction
  • Vitiligo - Overview
  • Vitiligo - Therapeutics Development
  • Vitiligo - Therapeutics Assessment
  • Vitiligo - Companies Involved in Therapeutics Development
  • Vitiligo - Drug Profiles
  • Vitiligo - Dormant Projects
  • Vitiligo - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Vitiligo, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Vitiligo - Pipeline by 2A Pharma AB, H1 2020
  • Vitiligo - Pipeline by Aclaris Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Amgen Inc, H1 2020
  • Vitiligo - Pipeline by AnTolRx Inc, H1 2020
  • Vitiligo - Pipeline by Arrien Pharmaceuticals LLC, H1 2020
  • Vitiligo - Pipeline by Boston Pharmaceuticals Inc, H1 2020
  • Vitiligo - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Vitiligo - Pipeline by Castle Creek Biosciences Inc, H1 2020
  • Vitiligo - Pipeline by Clinuvel Pharmaceuticals Ltd, H1 2020
  • Vitiligo - Pipeline by Incyte Corp, H1 2020
  • Vitiligo - Pipeline by Innovision Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
  • Vitiligo - Pipeline by JN Biosciences LLC, H1 2020
  • Vitiligo - Pipeline by Pfizer Inc, H1 2020
  • Vitiligo - Pipeline by Portola Pharmaceuticals Inc, H1 2020
  • Vitiligo - Pipeline by Radikal Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Rheos Medicines Inc, H1 2020
  • Vitiligo - Pipeline by Temprian Therapeutics Inc, H1 2020
  • Vitiligo - Pipeline by Villaris Therapeutics Inc, H1 2020
  • Vitiligo - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Vitiligo, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 2A Pharma AB
  • Aclaris Therapeutics Inc
  • Amgen Inc
  • AnTolRx Inc
  • Arrien Pharmaceuticals LLC
  • Boston Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Castle Creek Biosciences Inc
  • Clinuvel Pharmaceuticals Ltd
  • Incyte Corp
  • Innovision Therapeutics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • JN Biosciences LLC
  • Pfizer Inc
  • Portola Pharmaceuticals Inc
  • Radikal Therapeutics Inc
  • Rheos Medicines Inc
  • Temprian Therapeutics Inc
  • Villaris Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll